{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:32:02Z","timestamp":1779931922937,"version":"3.53.1"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":296,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Case Reports in Psychiatry"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Bupropion is an atypical antidepressant indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and smoking cessation. It is also used off\u2010label for attention deficit hyperactivity disorder (ADHD). Its mechanism of action includes the selective norepinephrine and dopamine reuptake inhibitor (NDRI). The drug is available in immediate\u2010release (IR), sustained\u2010release (SR), and extended\u2010release (XL) formulations. Common side effects are typically mild and include anxiety, insomnia, headache, dizziness, constipation, and nausea. Rarely, cutaneous hypersensitivity reactions may occur. We describe a 23\u2010year\u2010old man who developed severe and diffuse urticaria and angioedema 4 weeks after initiation of bupropion XL for MDD and ADHD. The bupropion was stopped, and he was treated with levocetirizine, diphenhydramine (oral and topical), and methylprednisolone with complete resolution of his symptoms within 2 weeks. Due to a good initial therapeutic response to the medication, a trial of bupropion SR was initiated. The patient again had a favorable therapeutic response without any dermatologic side effects.<\/jats:p>","DOI":"10.1155\/2024\/6638911","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T09:40:00Z","timestamp":1729676400000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tolerance of Bupropion SR After Delayed\u2010Onset Urticaria and Angioedema Associated With Bupropion XL"],"prefix":"10.1155","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5960-1423","authenticated-orcid":false,"given":"Faisal R.","family":"Elali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-8065","authenticated-orcid":false,"given":"Arthur C.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"e_1_2_9_1_2","unstructured":"NIMH Major Depression 2023 https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression."},{"key":"e_1_2_9_2_2","unstructured":"BainsN.andAbdijadidS. Major Depressive Disorder 2020 1\u2013189."},{"key":"e_1_2_9_3_2","unstructured":"HueckerM. R. SmileyA. andBupropionS. A. xPharm: The Comprehensive Pharmacology Reference 2022 1\u20134."},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045125316629071"},{"key":"e_1_2_9_5_2","unstructured":"U.S. Food and Drug Administration HIGHLIGHTS of PRESCRIBING INFORMATION 2017 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018644s052lbl.pdf?ref=raisan-21."},{"key":"e_1_2_9_6_2","unstructured":"U.S. Food and Drug Administration Bupropion Hydrochloride: Prescribing Information\u2014FDA 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/018644s039s040.pdf."},{"key":"e_1_2_9_7_2","article-title":"Bupropion-Induced Delayed-Onset Anaphylaxis","volume":"17","author":"Risma C. J.","year":"2015","journal-title":"The Primary Care Companion for CNS Disorders"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080064"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19297"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.6.621"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18297"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.19l02508"},{"key":"e_1_2_9_13_2","unstructured":"U.S. Food and Drug Administration MEDICATION GUIDE WELLBUTRIN XL\u00ae (WELL Byu-Trin) 2009 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021515s025MedGuide.pdf."},{"key":"e_1_2_9_14_2","unstructured":"U.S. Food and Drug Administration WELLBUTRIN SR\u00ae (Bupropion Hydrochloride) Sustained-Release Tablets 2001 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2001\/20358s19lbl.pdf."},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v07n0305"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.4.588"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.01.004"}],"container-title":["Case Reports in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2024\/6638911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T09:40:07Z","timestamp":1729676407000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2024\/6638911"}},"subtitle":[],"editor":[{"given":"Lut","family":"Tamam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1155\/2024\/6638911"],"URL":"https:\/\/doi.org\/10.1155\/2024\/6638911","archive":["Portico"],"relation":{},"ISSN":["2090-682X","2090-6838"],"issn-type":[{"value":"2090-682X","type":"print"},{"value":"2090-6838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2024-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"6638911"}}